• LAST PRICE
    6.5283
  • TODAY'S CHANGE (%)
    Trending Down-0.1117 (-1.6822%)
  • Bid / Lots
    5.0000/ 1
  • Ask / Lots
    8.1000/ 3
  • Open / Previous Close
    6.6900 / 6.6400
  • Day Range
    Low 6.5000
    High 6.6900
  • 52 Week Range
    Low 6.1101
    High 9.8800
  • Volume
    7,850
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 6.64
TimeVolumeCSBR
01:44 ET2006.645
01:45 ET59116.5401
01:54 ET1346.5
03:19 ET1006.5
03:46 ET2006.515
03:50 ET3006.5283
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCSBR
Champions Oncology Inc
89.8M
269.3x
---
United StatesOPNT
Opiant Pharmaceuticals Inc
104.5M
-3.1x
---
United StatesMREO
Mereo Biopharma Group PLC
99.4M
-0.1x
---
United StatesCDTX
Cidara Therapeutics Inc
34.6M
-0.9x
---
United StatesFIXX
Homology Medicines Inc
82.2M
-15.1x
---
United StatesIKNA
Ikena Oncology Inc
99.3M
-2.0x
---
As of 2022-12-09

Company Information

Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverages the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.

Contact Information

Headquarters
SUITE 619, 855 N. WOLFE STREETBALTIMORE, MD, United States 21205
Phone
410-369-0365
Fax
302-636-5454

Executives

Independent Chairman of the Board
Joel Ackerman
Chief Executive Officer, Director
Ronnie Morris
Chief Financial Officer
David Miller
Lead Independent Director
David Sidransky
Independent Director
Robert Brainin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$89.8M
Revenue (TTM)
$51.6M
Shares Outstanding
13.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.84
EPS
$0.02
Book Value
$0.67
P/E Ratio
269.3x
Price/Sales (TTM)
1.7
Price/Cash Flow (TTM)
39.6x
Operating Margin
0.97%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.